---
layout: default
title: Testosterone Cypionate
parent: 僅模型預測 (L5)
nav_order: 962
evidence_level: L5
indication_count: 10
---

# Testosterone Cypionate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Testosterone Cypionate: From Testosterone Deficiency to Urethral Obstruction Sequence

## One-Sentence Summary

Testosterone cypionate is a long-acting injectable androgen ester used clinically for testosterone deficiency (hypogonadism) in males. The TxGNN model's top-ranked prediction is **Urethral Obstruction Sequence**, but this prediction currently has **no supporting clinical trials or literature**, and the model's own rationale flags it as lacking a plausible mechanistic link — corresponding to the lowest evidence tier (L5).

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in the Singapore regulatory dataset (drug is not marketed); based on known pharmacology, testosterone cypionate is an androgen ester used for testosterone deficiency/hypogonadism |
| Predicted New Indication | Urethral obstruction sequence |
| TxGNN Prediction Score | 98.30% |
| Evidence Level | L5 |
| Singapore Market Status | 未上市 (Not marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for this drug in the evidence pack. Based on known pharmacology, testosterone cypionate is a synthetic androgen ester whose efficacy in treating male hypogonadism/testosterone deficiency is well established.

However, for the top-ranked predicted indication — urethral obstruction sequence — the model's own rationale states there is "no clear direct mechanistic relationship" between this structural urogenital anomaly and androgen signaling; the association appears to be driven purely by embedding similarity in the knowledge graph, without any supporting clinical or mechanistic evidence.

It is worth noting that several **lower-ranked** candidates in this evidence pack (polysomy of X chromosome, testicular regression syndrome, penile/testicular agenesis) have a much stronger and more direct biological rationale — these are conditions causing primary hypogonadism, for which testosterone replacement is standard clinical practice. These were assigned a higher evidence tier (L4, decision stage S1, "Research Question") than the top-ranked candidate, but still lack any trial or literature evidence within this dataset. They may warrant a separate, targeted evidence search rather than reliance on the current top-ranked prediction.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Singapore Market Information

This drug currently holds no marketing authorization in Singapore (0 registrations, market status: not marketed). No license records are available.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked predicted indication (urethral obstruction sequence) has no clinical trial or literature support and a mechanistic rationale explicitly assessed as weak/absent (L5, "Hold" per the model's own scoring). Combined with the drug's unmarketed status in Singapore and missing MOA/safety data, there is currently no basis to advance this specific candidate.

**To proceed, the following is needed:**
- Confirm original indication and mechanism of action (MOA) via DrugBank or another authoritative source (currently flagged as data gaps DG001/DG002)
- Obtain HSA/regulatory label data (warnings, contraindications) before any safety assessment
- If pursuing repurposing, redirect evidence collection toward the mechanistically stronger candidates (polysomy of X chromosome, testicular regression syndrome, penile/testicular agenesis) rather than the top TxGNN-ranked but mechanistically unsupported candidate
- Note: literature retrieved for "dyschondrosteosis-nephritis syndrome" (rank 9) was reviewed and found to be a database mismatch (articles pertain to unrelated conditions such as Klinefelter syndrome, HIV-associated hypogonadism, and post-vasectomy pain) — this should not be counted as supporting evidence for that indication
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

